Health
Sanofi and GSK initiate global Phase 3 clinical efficacy study of COVID-19 vaccine candidate – BioSpace
Sanofi and GSK started enrollment in their Phase 3 clinical study to assess the safety, efficacy, and immunogenicity of their adjuvanted recombinant-protein COVID-19…
Sanofi and GSK initiateglobal Phase 3clinical efficacy study of COVID-19 vaccinecandidate
- Two-stage design will evaluate vaccine formulations targeting original D.614 virus as well as B.1.351 variant, in diverse geographies with multiple circulating variants
- A booster study program will begin in the coming weeks to complement Phase 3 trial
- Pending positive Phase 3 outcomes and regulatory reviews, the vaccine could be approved in Q4 2021
PARIS and LONDON May 27, 2021 Today, Sanofi and GSK started enrollment…
Continue Reading
-
Business18 hours agoWhy is Alphabet stock worth less than Nvidia, Microsoft, Apple, and Amazon even though it is the most profitable S&P 500 company?
-
Noosa News17 hours ago‘Sunny, benign’ school holiday weather after morning showers in parts of Queensland
-
Noosa News14 hours agoTips to improve engagement – Proctor
-
General24 hours agoJordan Thompson retires from Wimbledon round-of-16 match with American Taylor Fritz